SIEMENS HEALTHINEERS AG Siemens Healthineers AG Stock Börse Stuttgart
Equities
SHL1
US82622J1043
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.8 EUR | -1.53% |
|
+6.50% | +0.77% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 22.67B 24.54B | Sales 2025 * | 24.26B 26.26B | Capitalization | 59.23B 64.11B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.04B 2.21B | Net income 2025 * | 2.57B 2.78B | EV / Sales 2024 * | 3.15 x |
| Net Debt 2024 * | 12.18B 13.18B | Net Debt 2025 * | 10.5B 11.36B | EV / Sales 2025 * | 2.87 x |
| P/E ratio 2024 * |
29.1
x | P/E ratio 2025 * |
23
x | Employees | - |
| Yield 2024 * |
1.9% | Yield 2025 * |
2.34% | Free-Float | 23.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Siemens Healthineers AG
More recommendations
More press releases
More news
| 1 week | +6.50% | ||
| Current month | +2.34% | ||
| 1 month | -1.50% | ||
| 3 months | -1.50% | ||
| 6 months | +9.17% | ||
| Current year | +0.77% |
1 week
25.20
26.20
1 month
24.4026.40
3 years
20.0034.80
5 years
14.2034.80
| Managers | Title | Age | Since |
|---|---|---|---|
Bernhard Montag
CEO | Chief Executive Officer | 55 | 17-12-31 |
Jochen Schmitz
DFI | Director of Finance/CFO | 57 | 17-12-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dow Wilson
BRD | Director/Board Member | 64 | 22-10-31 |
Peer Schatz
BRD | Director/Board Member | 57 | 21-03-22 |
| Director/Board Member | 72 | 18-02-28 |
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 25.8 | -1.53% |
| 24-05-14 | 26.2 | +0.77% |
| 24-05-13 | 26 | +0.78% |
| 24-05-10 | 25.8 | +0.78% |
| 24-05-09 | 25.6 | 0.00% |
Delayed Quote Börse Stuttgart, May 15, 2024 at 02:08 am EDT
More quotes
Siemens Healthineers AG is one of the world's No.1 manufacturers of equipment for medical imaging, laboratory diagnostics and hospital information systems. In addition, the group is developing digital health services and services dedicated to health establishments. Net sales break down by activity as follows:
- sale of imaging equipment and solutions (53%);
- sale of diagnostic equipment (21%);
- sale of solutions and services for cancer care (16.6%);
- sale of advanced therapeutic solutions (9.4%): for image-guided minimally invasive treatments in the areas of cardiology, interventional radiology and surgery.
Net sales are distributed geographically as follows: Germany (4.9%), Europe/CIS/Africa/Middle East (27.3%), the United States (34.6%), America (6.3%), China (13%) and Asia/Pacific and Japan (13.9%).
Calendar
2024-05-14
- Redburn Canada Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
53.08
EUR
Average target price
60.47
EUR
Spread / Average Target
+13.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.06% | 227B | |
| +12.07% | 192B | |
| +13.88% | 136B | |
| +27.12% | 108B | |
| +13.39% | 52.1B | |
| +6.74% | 51.87B | |
| +8.81% | 44.33B | |
| +4.14% | 36.75B | |
| +25.48% | 31.71B |
- Stock Market
- Equities
- SHL Stock
- SHL1 Stock